Immunologic Research

, Volume 65, Issue 1, pp 117–119 | Cite as

Erratum to: Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

  • Beniamino Palmieri
  • Dimitri Poddighe
  • Maria Vadalà
  • Carmen Laurino
  • Carla Carnovale
  • Emilio Clementi
Erratum

Erratum to: Immunol Res DOI 10.1007/s12026-016-8820-z

The original version of this article unfortunately contained a mistake. It has been corrected with this erratum. And the original article was also corrected.
  1. 1.

    The co-corresponding author of the article is Dr. Dimitri Poddighe (dimimedpv@yahoo.it).

     
  2. 2.

    Prof. Beniamino Palmieri and Dr. Dimitri Poddighe contributed equally to the drafting and writing of this study.

     
  3. 3.

    The correct version of Tables 3 and 5 are given below.

     
Table 3

Description of ADRs related to HPV immunization

 

After first dose

After second dose

After third dose

Symptoms (within 5 days post-vaccination)

   

Injection site reactions

Pain

2

2

1

Uncontrollable and involuntary movement of the limb

1

  

Swelling

1

1

 

Systemic reactions

 

Low-grade fever

3

5

1

Headache

5

5

2

Recurrent syncope

4

3

 

Persistent convulsive hunger

1

  

Irritability

1

2

 

Epileptic seizures

 

1

 

Temporary speech loss

 

1

 

Lower limbs paraesthesia and paresis

 

1

 

Hot flushes

 

1

 

Severe stomach pain

2

1

1

Insomnia

3

2

 

Hypersensitivity reactions

1

  

Leg muscle pain (myalgia)

1

3

1

Gait and orthostatic posture impairment

 

1

 

Excessive sweating

1

  

Vomiting

1

  

Symptoms (5–15 days post-vaccination)

Systemic reactions

Asthenia

2

5

1

Persistent thirst

 

3

 

Severe hands and feet itching

1

  

Optic neuritis

1

  

Symptoms (15–20 days post-vaccination)

Systemic reactions

Amenorrhoea

 

1

 

Skin rashes

1

1

 

Tachycardia

 

1

1

Difficult breathing

 

1

 

Weight loss

 

1

 
Table 5

Proposed diagnostic criteria of autoimmune/inflammatory syndrome induced by adjuvants (ASIA)

Major criteria

Previous exposure to an external stimulus (i.e. vaccine, adjuvant, silicone, nucleic acids, fragments of bacterial cell walls)

One of the following “typical” manifestations:

Myalgia/myositis, muscle weakness

Arthralgia and/or arthritis

Chronic fatigue, non-refreshing sleep or sleep disturbances

Neurological manifestations (especially if associated with demyelination)

Memory loss and cognitive impairment

Fever

Dry mouth

Improvement of symptoms after the removal of the triggering agent

Typical biopsy of the involved organs

Minor criteria

Appearance of autoantibodies or autoantibodies directed against the suspected adjuvant

Other clinical manifestations (i.e. functional somatic syndromes)

Association with specific HLA haplotypes (i.e. HLA-DRB1, HLA-DQB1)

Development of autoimmune diseases

Diagnostic requirements:

Two major criteria

One major criteria + two minor criteria

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Beniamino Palmieri
    • 1
  • Dimitri Poddighe
    • 2
  • Maria Vadalà
    • 1
  • Carmen Laurino
    • 1
  • Carla Carnovale
    • 3
  • Emilio Clementi
    • 3
  1. 1.Department of General Surgery and Surgical SpecialtiesUniversity of Modena and Reggio Emilia Medical School, Surgical ClinicModenaItaly
  2. 2.Department of PaediatricsASST Melegnano e MartesanaVizzolo PredabissiItaly
  3. 3.Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, National Research Council-Institute of Neuroscience, University Hospital L. SaccoUniversity of MilanoMilanItaly

Personalised recommendations